查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371925

到 2030 年急性淋巴性白血病市場預測：按類型、治療方法、年齡層、給藥途徑、診斷、最終用戶和地區進行的全球分析

Acute Lymphoblastic Leukemia Market Forecasts to 2030 - Global Analysis By Type, Treatment, Age Group, Route of Administration, Diagnosis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球急性淋巴性白血病（ALL）市場規模將達26.7億美元，預測期內年複合成長率為6.6%，預計到2030年將達到41.7億美元。

一種稱為急性淋巴性白血病 (ALL) 的癌症是由不成熟的淋巴球發展而來。急性是指白血病進展迅速並擴散至全身。 ALL 的發生始於骨髓，並迅速擴散至肝臟、脾臟、淋巴結、肝臟、中樞神經系統、脾臟和血液。體重減輕、呼吸急促、食慾不振、蒼白、瘀傷、頻繁且嚴重的牙齦出血以及流鼻血只是一些特異性症狀。

美國癌症協會的調查顯示，2023年美國將新增約6,540例急性淋巴性白血病新患者，其中男性3,660例，女性2,880例。死亡率約 1,390 人，其中男性死亡 700 人，女性死亡 690 人。

老年人口增加

隨著世界人口高齡化，對處方藥、護理和醫療等醫療保健服務的需求不斷增加。這種人口結構的變化為醫療保健提供者和製藥公司提供了滿足人口老化需求的機會。由於與老齡化相關的疾病和慢性病，老年人經常要求額外的醫療保健服務，這推動了該領域的成長。

醫療保健領域的法規挑戰

困難且不斷變化的法規環境是醫療保健部門面臨的最大障礙之一。各國的醫療法律各不相同，並且經常更新。對於醫療保健提供者和製藥公司來說，應對法規挑戰可能既耗時又昂貴，導致新藥物和服務的開發和交付延遲。這些法規負擔可能會阻礙醫療保健產業的業務擴張和創新。

加強政府配合措施

許多政府機構正在採取措施進行活動，使用最新的抗癌藥物來尋找癌細胞並幫助個人治癒。政府也向許多醫學研究機構提供資金，支持製藥公司開發尖端的癌症治療技術和藥物。隨著時間的推移，這些方面正在增加市場需求。

副作用和不良反應

儘管白血病藥物有好處，但不良反應和副作用預計將限制市場擴張。各種治療方法都可能產生負面影響，例如化療，可能會導致感染疾病、皮膚病、脫髮和其他問題。標靶治療的副作用包括噁心、腹瀉、脫髮和肝臟病變。此外，各種治療方法都有一定的副作用，可能會減慢白血病治療方案的採用速度。

COVID-19 的影響：

COVID-19 對醫療保健產業既有有利的影響，也有不利的影響。世界各國政府實施了封鎖，破壞了醫療保健產業藥品的供需平衡。大多數公司在主要國家都有製造業務，疫情對各種醫療保健產品的業務收益產生了重大影響。然而，重要的疾病，包括癌症、心血管疾病和其他嚴重的醫療問題，都會得到常規治療。白血病藥物銷售受疫情影響略為影響。

預計預測期內化療領域規模最大

預計化療領域在預測期內將佔據最大佔有率。這是因為它能夠破壞白血病細胞並阻止惡性細胞生長和複製，從而減緩疾病的傳播。 ALL 採用化療，使用單一或多重作用的藥物進行治療。此治療中使用細胞毒性物質、抗代謝物、烷化物質和其他植物衍生物。

預計小兒科在預測期內年複合成長率

領域小兒科在預測期內將經歷最高的年複合成長率。這是由於兒童中急性淋巴性/淋巴球白血病的患病很高。兒童最常見的癌症之一是急性淋巴性白血病。此外，兒童族群中急性淋巴性白血病的治療成功率較高。

比最大的地區

由於治療方法容易取得、治療成本高昂以及存在大量主要企業，預計北美在預測期內將佔據最大的市場佔有率。這一巨大市場佔有率背後的主要要素是美國領先製造商的存在、成熟的醫療基礎設施和技術創新。此外，不斷擴大的私人醫療機構和具有高購買力的消費者預計將在整個預測期內推動市場擴張。

複合年複合成長率最高的地區：

由於亞太地區人口眾多且患者對癌症治療的認知不斷提高，預計亞太地區在預測期內將維持最高的年複合成長率。這是由於批准的治療方法越來越多，以及政府和製藥公司加強配合措施提高該地區對該疾病的認知。政府在醫療保健方面的支出增加可能會在預測期內推動市場。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球急性淋巴性白血病市場：按類型

  • T細胞淋巴球白血病
  • B細胞急性淋巴性白血病
  • 費城染色體
  • 其他類型

第6章 全球急性淋巴性白血病市場：依治療分類

  • 放射治療
  • 標靶治療
  • 免疫療法
  • 骨髓移植
  • 化療
  • 幹細胞移植
  • 其他治療方法

第7章 全球急性淋巴性白血病市場：依年齡層

  • 成人
  • 小兒科

第8章 全球急性淋巴性白血病市場：依給藥途徑

  • 可注射的
  • 口服

第9章 全球急性淋巴性白血病市場：依診斷分類

  • 脊椎穿刺和腦脊髓液 (CSF) 分析
  • 骨髓抽吸和切片檢查
  • 免疫表現型分析
  • 血液常規檢查(CBC) 和分類
  • 流式細胞儀
  • 聚合酶鍊式反應 (PCR)
  • 下一代定序（NGS）
  • 微量殘存疾病(MRD) 檢測
  • 其他診斷

第10章 全球急性淋巴性白血病市場：依最終用戶分類

  • 診所
  • 醫院
  • 零售藥房
  • 其他最終用戶

第11章全球急性淋巴性白血病市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Jazz Pharmaceuticals
  • Erytech Pharma
  • GlaxoSmithKline Plc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • GlaxoSmithKline Plc.
  • Kite Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Leadiant Biosciences Inc.
  • Spectrum Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.
  • Baxter International Inc.
Product Code: SMRC23982

According to Stratistics MRC, the Global Acute Lymphoblastic Leukaemia (ALL) Market is accounted for $2.67 billion in 2023 and is expected to reach $4.17 billion by 2030 growing at a CAGR of 6.6% during the forecast period. A cancerous condition called acute lymphoblastic leukemia (ALL) arises from immature lymphocytes. Acute refers to leukemia that advances swiftly and disseminates throughout the body. The development of ALL begins in the bone marrow and spreads fast to the liver, spleen, lymph nodes, liver, central nervous system, spleen, and blood. Weight loss, shortness of breath, lack of appetite, paler complexion, bruises, frequent and severe bleeding gums, and nasal bleeds are only a few examples of non-specific symptoms.

According to the American Cancer Society research, acute lymphocytic leukemia in the US for 2023 is about 6,540 new cases, of which 3,660 were male and 2,880 females. The mortality is about 1,390 700 in males and 690 in females.

Market Dynamics:

Driver:

Increasing geriatric population

The need for healthcare services, such as prescription drugs, long-term care, and medical treatments, is increasing as the world's population continues to age. Healthcare providers and pharmaceutical firms now have the chance to meet the demands of the senior population thanks to this demographic shift. Due to age-related diseases and chronic ailments, older people frequently demand an additional healthcare service, which propels the sector's growth.

Restraint:

Regulatory challenges in healthcare

The difficult and constantly shifting regulatory environment is one of the biggest obstacles facing the healthcare sector. Health care laws differ from nation to nation and are often updated. For healthcare providers and pharmaceutical firms, navigating regulatory issues can take time and money, which might delay the creation and provision of novel medicines and services. The healthcare sector's ability to expand and innovate may be hampered by this regulatory load.

Opportunity:

Growing government initiatives

Numerous government agencies are taking steps to create campaigns where modern cancer medicines are employed to find cancer cells and aid individuals in curing themselves of the disease. Government funding is also given to a number of medical research organizations, which aid pharmaceutical companies in creating cutting-edge cancer treatment technology and medications. This aspect has increased market demand over time.

Threat:

Side effects & adverse reactions

Despite the benefits of leukemia treatment items, unfavorable responses and side effects are anticipated to constrain market expansion. A variety of therapies can have negative side effects, such as chemotherapy, which can cause infections, skin conditions, hair loss, and other issues. Adverse effects from targeted therapy might include nausea, diarrhea, hair loss, and liver issues. Additionally, various treatment options have certain side effects that might reduce the pace at which leukemia therapeutic solutions are adopted.

COVID-19 Impact:

The COVID-19 has had both beneficial and negative effects on the healthcare sector. Lockdowns were enacted by the governments, which caused an imbalance in the supply and demand of pharmaceutical items in the healthcare industry. The majority of businesses have manufacturing operations in important nations, where the pandemic has had a big impact on business revenues for a variety of healthcare items. However, important illnesses including cancer, cardiovascular disease, and other serious medical issues have received regular care. Sales of treatment products for leukemia have been slightly impacted by the epidemic.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is expected to be the largest during the forecast period. This is because it has the ability to destroy leukemia cells and prevent malignant cells from proliferating and replicating, slowing the spread of the disease. ALL is treated with chemotherapy using drugs with a single impact or several effects. Cytotoxic substances, antimetabolites, alkylating substances, and other plant derivatives are all used in this treatment.

The pediatrics segment is expected to have the highest CAGR during the forecast period

The pediatrics segment is expected to have the highest CAGR during the forecast period. The high prevalence of acute lymphocytic/lymphoblastic leukemia in the pediatric population is to blame for this. One of the most prevalent cancer forms in children is acute lymphoblastic leukemia. Additionally, the success rate of therapy for acute lymphoblastic leukemia is greater in the pediatric population.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to easy availability of treatments, high cost of treatments, and presence of majority of key players. The key factors that contribute to its huge market share are the existence of significant manufacturers in the United States, together with a well-established healthcare infrastructure and technological innovation. Additionally, expanding private healthcare organizations and consumers with high buying power are projected to fuel market expansion throughout the projection period.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to its high population base and rise in patient awareness toward cancer care. This is due to an increase in the number of medications for treatment receiving approval, as well as increased efforts by the government and pharmaceutical companies to raise awareness of the condition in this area. During the projected period, rising government spending on healthcare is likely to drive the market.

Key players in the market:

Some of the key players in Acute Lymphoblastic Leukaemia Market include: Amgen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Jazz Pharmaceuticals, Erytech Pharma, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline Plc., Kite Pharma, Inc., Novartis AG, Pfizer Inc., Sanofi, Leadiant Biosciences Inc., Spectrum Pharmaceuticals Inc., Thermo Fisher Scientific Inc. and Baxter International Inc.

Key Developments:

In October 2023, Thermo Fisher Scientific Inc. announced the completion of its acquisition of The Binding Site Group, a global leader in specialty diagnostics. The acquisition will aid in the growth of the specialty diagnostics market.

In July 2023, the introduction of PERCLOT Absorbable Hemostatic Powder in the U.S. was announced by Baxter International Inc., a leader in advancing surgical innovation worldwide. For patients with intact coagulation, PERCLOT is a passive, absorbable hemostatic powder that is ready to use and intended to stop minor bleeding

In June 2023, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL).

Types Covered:

  • T-cell Lymphoblastic Leukemia
  • B-cell Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome
  • Other Types

Treatments Covered:

  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy
  • Bone Marrow Transplant
  • Chemotherapy
  • Stem Cell Transplantation
  • Other Treatments

Age Groups Covered:

  • Adults
  • Pediatrics

Route of Administrations Covered:

  • Injectable
  • Oral

Diagnosis Covered:

  • Spinal Tap and Cerebrospinal Fluid (CSF) Analysis
  • Bone Marrow Aspiration and Biopsy
  • Immunophenotyping
  • Complete Blood Count (CBC) and Differential
  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Minimal Residual Disease (MRD) Testing
  • Other Diagnosis

End Users Covered:

  • Clinics
  • Hospitals
  • Retail Pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Lymphoblastic Leukemia Market, By Type

  • 5.1 Introduction
  • 5.2 T-cell Lymphoblastic Leukemia
  • 5.3 B-cell Acute Lymphoblastic Leukemia
  • 5.4 Philadelphia Chromosome
  • 5.5 Other Types

6 Global Acute Lymphoblastic Leukemia Market, By Treatment

  • 6.1 Introduction
  • 6.2 Radiation Therapy
  • 6.3 Targeted Therapy
  • 6.4 Immunotherapy
  • 6.5 Bone Marrow Transplant
  • 6.6 Chemotherapy
  • 6.7 Stem Cell Transplantation
  • 6.8 Other Treatments

7 Global Acute Lymphoblastic Leukemia Market, By Age Group

  • 7.1 Introduction
  • 7.2 Adults
  • 7.3 Pediatrics

8 Global Acute Lymphoblastic Leukemia Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Injectable
  • 8.3 Oral

9 Global Acute Lymphoblastic Leukemia Market, By Diagnosis

  • 9.1 Introduction
  • 9.2 Spinal Tap and Cerebrospinal Fluid (CSF) Analysis
  • 9.3 Bone Marrow Aspiration and Biopsy
  • 9.4 Immunophenotyping
  • 9.5 Complete Blood Count (CBC) and Differential
  • 9.6 Flow Cytometry
  • 9.7 Polymerase Chain Reaction (PCR)
  • 9.8 Next-Generation Sequencing (NGS)
  • 9.9 Minimal Residual Disease (MRD) Testing
  • 9.10 Other Diagnosis

10 Global Acute Lymphoblastic Leukemia Market, By End User

  • 10.1 Introduction
  • 10.2 Clinics
  • 10.3 Hospitals
  • 10.4 Retail Pharmacy
  • 10.5 Other End Users

11 Global Acute Lymphoblastic Leukemia Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Amgen, Inc.
  • 13.2 Bristol-Myers Squibb Company
  • 13.3 Celgene Corporation
  • 13.4 Jazz Pharmaceuticals
  • 13.5 Erytech Pharma
  • 13.6 GlaxoSmithKline Plc.
  • 13.7 F. Hoffmann-La Roche Ltd.
  • 13.8 Genzyme Corporation
  • 13.9 GlaxoSmithKline Plc.
  • 13.10 Kite Pharma, Inc.
  • 13.11 Novartis AG
  • 13.12 Pfizer Inc.
  • 13.13 Sanofi
  • 13.14 Leadiant Biosciences Inc.
  • 13.15 Spectrum Pharmaceuticals Inc.
  • 13.16 Thermo Fisher Scientific Inc.
  • 13.17 Baxter International Inc.

List of Tables

  • Table 1 Global Acute Lymphoblastic Leukemia Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Acute Lymphoblastic Leukemia Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Acute Lymphoblastic Leukemia Market Outlook, By T-cell Lymphoblastic Leukemia (2021-2030) ($MN)
  • Table 4 Global Acute Lymphoblastic Leukemia Market Outlook, By B-cell Acute Lymphoblastic Leukemia (2021-2030) ($MN)
  • Table 5 Global Acute Lymphoblastic Leukemia Market Outlook, By Philadelphia Chromosome (2021-2030) ($MN)
  • Table 6 Global Acute Lymphoblastic Leukemia Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Acute Lymphoblastic Leukemia Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 8 Global Acute Lymphoblastic Leukemia Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 9 Global Acute Lymphoblastic Leukemia Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 10 Global Acute Lymphoblastic Leukemia Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 11 Global Acute Lymphoblastic Leukemia Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 12 Global Acute Lymphoblastic Leukemia Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 13 Global Acute Lymphoblastic Leukemia Market Outlook, By Stem Cell Transplantation (2021-2030) ($MN)
  • Table 14 Global Acute Lymphoblastic Leukemia Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Acute Lymphoblastic Leukemia Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 16 Global Acute Lymphoblastic Leukemia Market Outlook, By Adults (2021-2030) ($MN)
  • Table 17 Global Acute Lymphoblastic Leukemia Market Outlook, By Pediatrics (2021-2030) ($MN)
  • Table 18 Global Acute Lymphoblastic Leukemia Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Acute Lymphoblastic Leukemia Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 20 Global Acute Lymphoblastic Leukemia Market Outlook, By Oral (2021-2030) ($MN)
  • Table 21 Global Acute Lymphoblastic Leukemia Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 22 Global Acute Lymphoblastic Leukemia Market Outlook, By Spinal Tap and Cerebrospinal Fluid (CSF) Analysis (2021-2030) ($MN)
  • Table 23 Global Acute Lymphoblastic Leukemia Market Outlook, By Bone Marrow Aspiration and Biopsy (2021-2030) ($MN)
  • Table 24 Global Acute Lymphoblastic Leukemia Market Outlook, By Immunophenotyping (2021-2030) ($MN)
  • Table 25 Global Acute Lymphoblastic Leukemia Market Outlook, By Complete Blood Count (CBC) and Differential (2021-2030) ($MN)
  • Table 26 Global Acute Lymphoblastic Leukemia Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 27 Global Acute Lymphoblastic Leukemia Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 28 Global Acute Lymphoblastic Leukemia Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 29 Global Acute Lymphoblastic Leukemia Market Outlook, By Minimal Residual Disease (MRD) Testing (2021-2030) ($MN)
  • Table 30 Global Acute Lymphoblastic Leukemia Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 31 Global Acute Lymphoblastic Leukemia Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Acute Lymphoblastic Leukemia Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 33 Global Acute Lymphoblastic Leukemia Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 34 Global Acute Lymphoblastic Leukemia Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 35 Global Acute Lymphoblastic Leukemia Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.